| Page 19 | Kisaco Research

Author:

Melissa Landon

Head, Commercial & Business Development, AI & Automation
MilliporeSigma

Dr. Melissa (“Mel”) Landon leads Commercial and Business Development for AI and Automation at Millipore Sigma, the Life Science business of Merck KGaA. With 20 years of experience of building cutting edge platforms across pharma and tech, Mel’s current work focuses on scaling intelligent automation and AI solutions that bridge scientific innovation with commercial value. She brings to this role a cross-disciplinary background spanning life sciences, technology partnerships, and enterprise transformation. Prior to joining MilliporeSigma, Melissa served as Chief Strategy Officer at Cyclica, an AI-enabled tech bio company (acquired by Recursion in 2023). Melissa completed her PhD in Bioinformatics at Boston University and performed postdoctoral studies in biochemistry and X-ray crystallography at Brandeis University. 

... read more

Melissa Landon

Head, Commercial & Business Development, AI & Automation
MilliporeSigma

Dr. Melissa (“Mel”) Landon leads Commercial and Business Development for AI and Automation at Millipore Sigma, the Life Science business of Merck KGaA. With 20 years of experience of building cutting edge platforms across pharma and tech, Mel’s current work focuses on scaling intelligent automation and AI solutions that bridge scientific innovation with commercial value. She brings to this role a cross-disciplinary background spanning life sciences, technology partnerships, and enterprise transformation. Prior to joining MilliporeSigma, Melissa served as Chief Strategy Officer at Cyclica, an AI-enabled tech bio company (acquired by Recursion in 2023). Melissa completed her PhD in Bioinformatics at Boston University and performed postdoctoral studies in biochemistry and X-ray crystallography at Brandeis University. 

 

Sagar Jain

Director, Digital AI Strategy SSF
Roche

Sagar Jain

Director, Digital AI Strategy SSF
Roche

Sagar Jain

Director, Digital AI Strategy SSF
Roche
 

Steve Gately

Client Director, Healthcare ISV Platforms
NVIDIA

Steve leads NVIDIA’s engagement with strategic ISV platform partners in the healthcare sector, helping them accelerate their go-to-market initiatives. By integrating partners’ specialized tools and data with NVIDIA’s advanced training and inference technologies, Steve and his team develop cohesive strategies that drive success across key AI-powered healthcare use cases.

Read full bio

Steve Gately

Client Director, Healthcare ISV Platforms
NVIDIA

Steve Gately

Client Director, Healthcare ISV Platforms
NVIDIA

Steve leads NVIDIA’s engagement with strategic ISV platform partners in the healthcare sector, helping them accelerate their go-to-market initiatives. By integrating partners’ specialized tools and data with NVIDIA’s advanced training and inference technologies, Steve and his team develop cohesive strategies that drive success across key AI-powered healthcare use cases.

 

Reed Few

Director of Data Science & External Innovation
J&J

Reed Few is Director of External Innovation for Data Science and Digital Health at Johnson and Johnson Innovative Medicine, R&D. With a background spanning real-world data, predictive modeling, and precision medicine, Reed is passionate about finding ways to combine data and AI to bring therapies from concept to approval, faster. In her current role, she looks for partnerships that will help to design better, more diverse clinical trials, improve operational efficiencies, and find digital endpoints that better reflect how patients live and feel in the real world.

Read full bio

Reed Few

Director of Data Science & External Innovation
J&J

Reed Few

Director of Data Science & External Innovation
J&J

Reed Few is Director of External Innovation for Data Science and Digital Health at Johnson and Johnson Innovative Medicine, R&D. With a background spanning real-world data, predictive modeling, and precision medicine, Reed is passionate about finding ways to combine data and AI to bring therapies from concept to approval, faster. In her current role, she looks for partnerships that will help to design better, more diverse clinical trials, improve operational efficiencies, and find digital endpoints that better reflect how patients live and feel in the real world. As of late, her focus has been on initiatives applying generative AI and large language models to accelerate document creation across preclinical, CMC, and clinical domains – advancing smarter, faster, and more connected drug development.

 

Dr. Eliezer Katz

CMO
Eledon Pharmaceuticals

Dr. Katz is an experienced transplant surgeon and a leader in clinical development in the pharmaceutical industry. Currently, Dr. Katz is the chief medical officer of Eledon Pharmaceutical. Before joining Eledon, Dr. Katz was CMO of eGenesis, a company in the xenotransplantation field. Previously, Dr. Katz served as Vice President and clinical development lead at Viela Bio and Horizon Therapeutics, where he was responsible for developing novel medications for autoimmune-related diseases and organ transplantation.

Read full bio

Dr. Eliezer Katz

CMO
Eledon Pharmaceuticals

Dr. Eliezer Katz

CMO
Eledon Pharmaceuticals

Dr. Katz is an experienced transplant surgeon and a leader in clinical development in the pharmaceutical industry. Currently, Dr. Katz is the chief medical officer of Eledon Pharmaceutical. Before joining Eledon, Dr. Katz was CMO of eGenesis, a company in the xenotransplantation field. Previously, Dr. Katz served as Vice President and clinical development lead at Viela Bio and Horizon Therapeutics, where he was responsible for developing novel medications for autoimmune-related diseases and organ transplantation.
Dr. Katz earned his MD degree from the Hebrew University-Hadassah Medical School in Jerusalem, Israel.
Dr. Katz joined Viela Bio/Horizon following 30 years of combined academic and pharmaceutical career in the areas of organ transplantation, immunology, and immune-induced diseases.
His academic career as a transplant surgeon spanned 20 years, including directorship of two transplantation programs. The director of the abdominal transplantation division at Integris Baptist Medical Center in Oklahoma City, and an associate professor of surgery and the director of the liver transplantation division at the University of Massachusetts Medical Center, Worcester, MA. During his tenure as a transplant surgeon, Dr. Katz implemented techniques for split liver and living donor liver transplantation, was actively involved in policy making related to organ donation and allocation and led efforts to increase organ donation.
After joining the pharmaceutical industry, Dr. Katz served as the vice president at CTI clinical trial and consulting services, as senior director in transplantation at Medicine Development Group, Pfizer Inc., and at Medimmune/AstraZeneca as a senior director at RIA (respiratory, inflammation, and autoimmunity), where he oversaw clinical development in neuro-inflammation, inflammatory bowel disease, and myositis.
Dr. Katz is an author of more than 60 peer-reviewed publications.

 

Martha Scott Poindexter

CEO
Animal Health Institute

Martha Scott Poindexter

CEO
Animal Health Institute

Martha Scott Poindexter

CEO
Animal Health Institute
 

Richard Kestenbaum

Retail Correspondent
Forbes

Richard Kestenbaum

Retail Correspondent
Forbes

Richard Kestenbaum

Retail Correspondent
Forbes
 

William Propst

Managing Director
Jones Lang LaSalle

Richard is a co-founder and Partner of Triangle Capital and has been an investment banker for over 35 years. Richard has a great deal of experience advising clients in merchandising businesses, particularly in the Retail & Consumer sector.  Richard is an often-quoted expert on the retail and merchandising industries. He is a Contributor to Forbes.com where he writes a regular blog about trends in retail and consumer product businesses. He also appears regularly in print and other media as well as industry panels and speaking programs.  

Read full bio

William Propst

Managing Director
Jones Lang LaSalle

William Propst

Managing Director
Jones Lang LaSalle

Richard is a co-founder and Partner of Triangle Capital and has been an investment banker for over 35 years. Richard has a great deal of experience advising clients in merchandising businesses, particularly in the Retail & Consumer sector.  Richard is an often-quoted expert on the retail and merchandising industries. He is a Contributor to Forbes.com where he writes a regular blog about trends in retail and consumer product businesses. He also appears regularly in print and other media as well as industry panels and speaking programs.  

Before co-founding Triangle, Richard was a Managing Director at a predecessor firm to Raymond James and before that he was a Partner and First Vice President at Drexel Burnham Lambert Inc.  At Drexel, Richard was responsible for a group of 14 professionals doing middle-market mergers and acquisitions around the world.

Richard is the co-author of three books on finance and computer programming.  He is formerly an Adjunct Assistant Professor of International Business at the graduate program of the Stern School of Business at New York University.  Richard received a BS in Accounting from New York University and an MBA with a concentration in Finance from Harvard University.  Richard is married and lives in New York.  

 

Kevin Weil

Chief Product Officer
OpenAI

Kevin Weil is Chief Product Officer at OpenAI, and a member of the Board of Directors of Cisco. In his current role as Chief Product Officer at OpenAI, Weil turns groundbreaking artificial intelligence research into practical, impactful solutions for over 500 million users, businesses, and developers globally. Prior to joining OpenAI, Weil served as the president of product and business for Planet Labs, cofounder of the Libra cryptocurrency, the vice president of product at Instagram, and the senior vice president of product at Twitter.

Read full bio

Kevin Weil

Chief Product Officer
OpenAI

Kevin Weil

Chief Product Officer
OpenAI

Kevin Weil is Chief Product Officer at OpenAI, and a member of the Board of Directors of Cisco. In his current role as Chief Product Officer at OpenAI, Weil turns groundbreaking artificial intelligence research into practical, impactful solutions for over 500 million users, businesses, and developers globally. Prior to joining OpenAI, Weil served as the president of product and business for Planet Labs, cofounder of the Libra cryptocurrency, the vice president of product at Instagram, and the senior vice president of product at Twitter.